APLS Q1 2024 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$172M+284.3% YoY

Gross Profit

$152M88.0% margin

Operating Income

-$62M-36.0% margin

Net Income

-$66M-38.5% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+17.7%

Cash Flow

Operating Cash Flow

-$133M

Free Cash Flow

-$133M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$832M

Total Liabilities

$565M

Stockholders' Equity

$267M

Cash & Equivalents

$327M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$172M	$45M	+284.3%
Gross Profit	$152M	$37M	+309.5%
Operating Income	-$62M	-$175M	+64.5%
Net Income	-$66M	-$178M	+62.6%

Revenue Segments

Product

$163M95%

Licensing And Other Revenue

$9M5%